ReviewFocus (American Psychiatric Publishing)2017
Parkinson's Disease: Cognitive Impairment.
Review in Focus (American Psychiatric Publishing), 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
17 citing papers in PubMed, 40 citations in OpenAlex.
- Boswellic acids as an adjunct therapy in Parkinson's disease: a double-blind clinical trial investigating on its effects on motor symptoms and inflammatory markers.Inflammopharmacology · 2025Trial
- Longitudinal untargeted metabolomics of cognitive impairment in Parkinson's disease.Alzheimer's & dementia : the journal of the Alzheimer's Association · 2026Article
- From clutter to confidence: home environmental triggers and adaptive solutions for freezing of gait in Parkinson's disease.Journal of neural transmission (Vienna, Austria : 1996) · 2026Review
- No Association Between Hypnotizability and Basal Ganglia Morphometry.Brain sciences · 2026Article
- Systematic review of unveiling the potential of AI using machine learning and deep learning methods in neurodegenerative diseases.PeerJ. Computer science · 2026Review
- Sense of agency and decision making.Frontiers in psychology · 2026Article
- Multimodal imaging and machine learning for diagnosis of Parkinson's disease with cognitive impairment: ASL and QSM as potential biomarkers.Frontiers in aging neuroscience · 2026Article
- Genotype-Based Housing as a Potential Confounder in Studies Using Transgenic Mouse Models-Insight from the A53T Mouse Model of Parkinson's Disease.Biomedicines · 2025Article
- Missed Insights for Earlier Management of Parkinson's Disease and the Value of Dopamine Transporter (DAT) Scans.Geriatrics (Basel, Switzerland) · 2024Article
- General Treatments Promoting Independent Living in Parkinson's Patients and Physical Therapy Approaches for Improving Gait-A Comprehensive Review.Medicina (Kaunas, Lithuania) · 2024Review
- Article
- The assessment of executive functions to test the integrity of the nigrostriatal network: A pilot study.Frontiers in psychology · 2023Article
- Review
- Spontaneous Object Exploration in a Recessive Gene Knockout Model of Parkinson's Disease: Development and Progression of Object Recognition Memory Deficits in MaleFrontiers in behavioral neuroscience · 2022Article
- Protocol for randomized controlled trial to evaluate the safety and feasibility of a novel helmet to deliver transcranial light emitting diodes photobiomodulation therapy to patients with Parkinson's disease.Frontiers in neuroscience · 2022Article
- A Mobile Application for Smart Computer-Aided Self-Administered Testing of Cognition, Speech, and Motor Impairment.Sensors (Basel, Switzerland) · 2020Article
- Neurocognitive Disorders in Geriatric Psychiatry.Focus (American Psychiatric Publishing) · 2017Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Cognitive deficits are important and emerging clinical targets for psychiatrists caring for patients with Parkinson's disease (PD), a neurodegenerative disorder commonly accompanied by mood and psychotic disturbances and identified by its progressive motor abnormalities. Over the course of the disease and across all its stages, virtually every individual with PD experiences some degree of cognitive deficit, ranging from mild cognitive impairment to dementia. Across this spectrum, cognitive impairments affect functioning and quality of life, often more than motor aspects of the disease. Advances in treatments for motor deficits in PD now render the clinical significance of cognitive dysfunction more obvious, including its impact on psychiatric presentations and their treatment. Since cognitive dysfunction is underdetected and undertreated in clinical practice, holistic psychiatric care of PD patients warrants appreciation of the clinical presentation, biopsychosocial features, and treatment of cognitive impairment. Future directions for research and clinical care also discussed.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.